Fennec Pharmaceuticals (TSE:FRX) Stock Crosses Below 50-Day Moving Average – Time to Sell?

Fennec Pharmaceuticals Inc. (TSE:FRX)’s stock price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of C$6.89 and traded as low as C$6.40. Fennec Pharmaceuticals shares last traded at C$6.55, with a volume of 1,125 shares.

Fennec Pharmaceuticals Stock Up 11.6 %

The company’s 50 day moving average price is C$6.89 and its 200 day moving average price is C$8.90. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The firm has a market capitalization of C$179.21 million, a price-to-earnings ratio of 65.50 and a beta of 0.25.

Fennec Pharmaceuticals (TSE:FRX) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) EPS for the quarter, missing the consensus estimate of C$0.08 by C($0.35). The company had revenue of C$9.94 million for the quarter, compared to analyst estimates of C$18.67 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. As a group, research analysts forecast that Fennec Pharmaceuticals Inc. will post 0.6037736 earnings per share for the current fiscal year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.